Vascular injury and repair: A potential target for cell therapies

Future Cardiology

Volumn 11, Issue 1, 2015, Pages 45-60

  Mitchell, Andrew ^a   Fujisawa, Takeshi ^b   Newby, David ^a   Mills, Nicholas ^a   Cruden, Nicholas L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Atherosclerosis; cell therapy; endothelial progenitor cells; percutaneous coronary intervention; vascular injury

Indexed keywords

GROWTH FACTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIGNAL PEPTIDE;

ADVENTITIA; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL GRAFT; BLOOD VESSEL INJURY; CELL THERAPY; DISEASE COURSE; ENDOTHELIAL PROGENITOR CELL; HUMAN; INTIMA; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; PRIORITY JOURNAL; REVIEW; STENT; TISSUE ENGINEERING; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASCULAR SURGERY; ANIMAL; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL; COMPLICATION; INJURIES; PATHOLOGY; PHYSIOLOGY; RUPTURE; SMOOTH MUSCLE FIBER; TRANSPLANTATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; DISEASE PROGRESSION; ENDOTHELIAL PROGENITOR CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCYTES, SMOOTH MUSCLE; PERICYTES; PLAQUE, ATHEROSCLEROTIC; RUPTURE; STENTS; TISSUE ENGINEERING;

EID: 84921654975     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.14.77     Document Type: Review

References (116)

1. Tura O, Skinner EM, Barclay GR et al. Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 31(2), 338-348 (2013).
2. Phinikaridou A, Andia ME, Passacquale G, Ferro A, Botnar RM. Noninvasive MRI monitoring of the effect of interventions on endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent. J. Am. Heart Assoc. 2(5), 402-402 (2013).
3. Simova I, Katova T, Denchev S, Dimitrov N. Flow-mediated dilatation has an additive value to stress ECG for the diagnosis of angiographically significant coronary atherosclerosis. J. Am. Soc. Hypertens. 4(4), 203-208 (2010).
4. Huynh J. Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration. Sci. Transl. Med. 3(112), 112ra122 (2011).
5. Grage-Griebenow E, Flad H, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J. Leukoc. Biol. 69(1), 11-20 (2001).
6. Jaipersad AS, Lip GYH, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol. 63(1), 1-11 (2013).
7. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int. J. Cardiol. 130(2), 147-158 (2008).
8. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86(2), 515-581 (2006).
9. Newby DE, Wright RA, Labinjoh C et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99(11), 1411-1415 (1999).
10. Lang NN, Gudmundsdóttir IJ, Boon NA, Ludlam CA, Fox KA, Newby DE. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers. J. Am. Coll. Cardiol. 52(1), 33-39 (2008).
11. Kolb S, Vranckx R, Huisse M-G, Michel JB, Meilhac O. The phosphatidylserine receptor mediates phagocytosis by vascular smooth muscle cells. J. Pathol. 212(3), 249-259 (2007).
12. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 81(3), 999-1030. (2001).
13. Ho-Tin-Noe B, Michel JB. Initiation of angiogenesis in atherosclerosis: smooth muscle cells as mediators of the angiogenic response to atheroma formation. Trends Cardiovasc. Med. 21(7), 183-187 (2011).
14. Haurani MJ, Pagano PJ. Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: Bellwether for vascular disease? Cardiovasc. Res. 75(4), 679-689 (2007).
15. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J. Am. Coll. Cardiol. 55(15), 1553-1565 (2010).
16. Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ. Res. 114(1), 214-226 (2014).
17. Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306(8), 864-871 (2011).
18. Mauri L, Silbaugh TS, Wolf RE et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 118(18), 1817-1827 (2008).
19. Nakagawa M, Naruko T, Ikura Y et al. A decline in platelet activation and inflammatory cell infiltration is associated with the phenotypic redifferentiation of neointimal smooth muscle cells after bare-metal stent implantation in acute coronary syndrome. J. Atheroscler. Thromb. 17(7), 675-687 (2010).
20. Welt FGP, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler. Thromb. Vasc. Biol. 20(12), 2553-2558 (2000).
21. Tanguay J-F, Hammoud T, Geoffroy P, Merhi Y. Chronic platelet and neutrophil adhesion: a causal role for neointimal hyperplasia in in-stent restenosis. J. Endovasc. Ther. 10(5), 968-967 (2003).
22. Inoue T, Kato T, Hikichi Y et al. Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening. Thromb. Haemost. 95(1), 43-48 (2006).
23. Rittersma SZH, Meuwissen M, Loos CMVD et al. Eosinophilic infiltration in restenotic tissue following coronary stent implantation. Atherosclerosis 184(1), 157-162 (2006).
24. Yang A, Pizzulli L, Lüderitz B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb. Res. 117(4), 371-377 (2006).
25. Pietersma A, Kofflard M, De Wit LE et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 91(5), 1320-1325 (1995).
26. Morton, A, Arnold N, Gunn J et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc. Res. 68(3), 493-501 (2005).
27. Xia ZY, Yang H, Qu HQ, Cheng WD. Impact of carotid artery stenting on plasma interleukin-6, tumour necrosis factor and C-reactive protein. Int. Angiol. 31(1), 28-32 (2012).
28. Ezhov M. Interleukin 6 but not interleukin 10 is associated with restenosis after coronary stenting. Atherosclerosis 169(1), 193-194 (2003).
29. Rahel B. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc. Res. 60(1), 136-140 (2003).
30. Hojo Y. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 84(1), 83-87 (2000).
31. Tousoulis D, Papageorgiou N, Stefanadis C. Is C-reactive protein a prognostic marker after angioplasty? Heart 95(12), 957-959 (2009).
32. Kang WC, Moon II, Lee K et al. Comparison of inflammatory markers for the prediction of neointimal hyperplasia after percutaneous coronary intervention. A prospective study. Coron. Artery Dis. 22(8), 526-532 (2011).
33. Kubica J, Kozinski M, Krzewina-Kowalska A et al. Combined periprocedural evaluation of CRP and TNF-α enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int. J. Mol. Med. 16(1), 173-180 (2005).
34. Tanizawa S. Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart 75(6), 549 (1996).
35. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 93(3), 1266-1274 (1994).
36. Uchida K, Sasahara M, Morigami N, Hazama F, Kinoshita M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 124(1), 9-23 (1996).
37. Santiago Redondo JN, Navarro-Dorado J, Ramajo M et al. Age-dependent defective TGF-beta1 signaling in patients undergoing coronary artery bypass grafting. J. Cardiothorac. Surg. 9(1), 24 (2014).
38. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am. Heart J. 133(4), 387-392 (1997).
39. Furukawa Y, Matsumori A, Ohashi N et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ. Res. 84(3), 306-314 (1999).
40. Oshima S, Ogawa H, Hokimoto S et al. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ. J. 65(4), 261-264 (2001).
41. Ikeda U, Shimada K, Cipollone F, Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler. Thromb. Vasc. Biol. 21(6), 1090-1091 (2001).
42. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105(25), 2974-2980 (2002).
43. Schwartz RS, Huber KC, Murphy JG et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J. Am. Coll. Cardiol. 19(2), 267-274 (1992).
44. Nakano M, Otsuka F, Yahagi K et al. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur. Heart J. 34(42), 3304-3313 (2013).
45. Neži? DG, Kneževi? AM, Milojevi? PS et al. The fate of the radial artery conduit in coronary artery bypass grafting surgery. Eur. J. Cardiothorac. Surg. 30(2), 341-346 (2006).
46. Kaneda H, Terashima M, Takahashi T et al. Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: an intravascular ultrasound study. Am. Heart J. 151(3), 726-729 (2006).
47. Sepehripour A, Jarral O, Shipolini A, McCormack D. Does a 'no-touch' technique result in better vein patency? Interact. Cardiovasc. Thorac. Surg. 13, 626-630 (2011).
48. Chesebro JH, Fuster V, Elveback LR et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N. Engl. J. Med. 310(4), 209-214 (1984).
49. Newby AC. Coronary vein grafting: the flags keep waving but the game goes on. Cardiovasc. Res. 97(2), 193-194 (2013).
50. Stump M. Endothelium grown from circulating blood on isolated intravascular Dacron hub. Am. J. Pathol. 43, 361-367 (1963).
51. Shi Q, Wu MH-D, Hayashida N et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J. Vasc. Surg. 20(4), 546-557 (1994).
52. Asahara T. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-966 (1997).
53. Hill JM, Zalos G, Halcox JPJ et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348(7), 593-600 (2003).
54. Bonello L, Basire A, Sabatier F, Paganelle F, Dignat-George F. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease. J. Thromb. Haemost. 4(5), 979-981 (2006).
55. Marboeuf P, Corseaux D, Mouquet F, Van Belle E, Jude B, Susen S. Inflammation triggers CFU-EC mobilization after angioplasty in chronic lower limb ischemia. J. Thromb. Haemost. 6(1), 195-197 (2007).
56. Padfield GJ, Tura-Ceide O, Freyer E et al. Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease. Heart 99(11), 791-798 (2013).
57. Gill M, Dias S, Hattori K et al. Vascular trauma induces rapid but transient mobilization of VEGFR2+ AC133+ endothelial precursor cells. Circ. Res. 88(2), 167-174 (2001).
58. Peichev M Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 95(3), 952-958 (2000).
59. Timmermans F, Van Hauwermeiren F, De Smedt M et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler. Thromb. Vasc. Biol. 27(7), 1572-1579 (2007).
60. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105(1), 71-77 (2000).
61. Amini AR, Laurencin CT, Nukavarapu SP. Differential analysis of peripheral blood-and bone marrow-derived endothelial progenitor cells for enhanced vascularization in bone tissue engineering. J. Orthop. Res. 30(9), 1507-1515 (2012).
62. Tsuzuki M. Bone marrow-derived cells are not involved in reendothelialized endothelium as endothelial cells after simple endothelial denudation in mice. Basic Res. Cardiol. 104(5), 601-611 (2009).
63. Alessandri G, Girelli M, Taccagni G et al. Human vasculogenesis ex vivo: embryonal aorta as a tool for isolation of endothelial cell progenitors. Lab. Invest. 81(6), 875-885 (2001).
64. Ingram DA. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 105(7), 2783-2786 (2005).
65. Zengin E, Chalajour F, Gehling UM et al. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 133(8), 1543-1551 (2006).
66. Conway E, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49(3), 507-521 (2001).
67. Sun J-Y, Zhai L, Li Q-L et al. Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in Type 2 diabetic patients. Clinics 68(5), 665-673 (2013).
68. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions:the VAL-PREST trial. J. Invasive Cardiol. 13(2), 93-97 (2001).
69. Peters S, Trümmel M, Meyners W, Koehler B, Westermann K. Valsartan versus ACE inhibition after bare metal stent implantation-results of the VALVACE trial. Int. J. Cardiol. 98(2), 331-335 (2005).
70. Steinmetz M, Brouwers C, Nickenig G, Wassmann S. Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. J. Cell Mol. Med. 14(6B), 1645-1656 (2010).
71. Yu Y, Fukuda N, Yao E-H et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am. J. Hypertens. 21(1), 72-77 (2008).
72. Kobayashi N, Fukushima H, Takeshima H et al. Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am. J. Hypertens. 23(9), 1007-1013 (2010).
73. Jung C, Florvaag A, Oberle V et al. Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. J. Renin Angiotensin Aldosterone Syst. 13(3), 401-406 (2012).
74. fadini GP, Albiero M, Boscaro E et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol. Int. 34(7), 709-715 (2010).
75. Hibbert B, Ma X, Pourdjabbar A et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS ONE 6(1), e16413 (2011).
76. Paradisi G, Bracaglia M, Basile F et al. Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women. Clin. Exp. Obstet. Gynecol. 39(2), 153-159 (2012).
77. Pirro M, Schillaci G, Romagno PF et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J. Cardiovasc. Pharmacol. Ther. 14(1), 14-21 (2009).
78. Baran C, Durdu S, Dalva K et al. Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Rev. 8(3), 963-971 (2012).
79. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron. Artery Dis. 15(5), 235-242 (2004).
80. Spiel AO, Mayr FB, Leitner JM, Firbas C, Sieghart W, Jilma B. Simvastatin and rosuvastatin mobilize endothelial progenitor cells but do not prevent their acute decrease during systemic inflammation. Thromb. Res. 123(1), 108-113 (2008).
81. Sugiura T, Kondo T, Kureishi-Bando Y et al. Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension 52(3), 491-498 (2008).
82. de Ciuceis C, Pilu A, Rizzoni D et al. Effect of antihypertensive treatment on circulating endothelial progenitor cells in patients with mild essential hypertension. Blood Press. 20(2), 77-83 (2011).
83. Yao EH, Fukuda N, Matsumoto T et al. Effects of the antioxidative-blocker celiprolol on endothelial progenitor cells in hypertensive rats. Am. J. Hypertens. 21(9), 1062-1068 (2008).
84. Pistrosch F, Herbrig K, Oelschlaegel U et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183(1), 163-167 (2005).
85. Powell TM, Paul JD, Hill JM et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Atheroscler. Thromb. Vasc. Biol. 25(2), 296-301 (2005).
86. Körbling M, Reuben JM, Gao H et al. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 46(10), 1795-1802 (2006).
87. Kong D. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 110(14), 2039-2046 (2004).
88. Yoshioka T, Takahashi M, Shiba Y et al. Granulocyte colony-stimulating factor (G-CSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice. Cardiovasc. Res. 70(1), 61-69 (2006).
89. Kang HJ, Kim HS, Zhang SY et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363, 751-756 (2004).
90. Ince H, Valgimigli M, Petzsch M et al. Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart 94(5), 610-616 (2008).
91. Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol. 46(9), 1643-1648 (2005).
92. Steinwender C, Hofmann R, Kammler J et al. Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcoronary transplantation after primary stent implantation for acute myocardial infarction. Am. Heart J. 151(6), 1296.e7-13 (2006).
93. Suzuki K, Nagashima K, Arai M et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Jpn Circ. J. 70(4), 430-437 (2006).
94. Meier P, Gloekler S, de Marchi SF et al. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation 120(14), 1337-1338 (2009).
95. Werner N. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. 93(2), 17-24 (2003).
96. Gulati R. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 108(12), 1520-1526 (2003).
97. Zhao X, Huang L, Yin Y, Fang Y, Zhou Y. Autologous endothelial progenitor cells transplantation promoting endothelial recovery in mice. Transpl. Int. 20(8), 712-721 (2007).
98. Lasala GP, Silva JA, Gardner PA, Minguell JJ. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 61(6), 551-556 (2010).
99. Lasala GP, Silva JA, Kusnick BA, Minguell JJ. Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovasc. Revasc. Med. 12(1), 29-34 (2011).
100. Murphy MP, Lawson JH, Rapp BM et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J. Vasc. Surg. 53(6), 1565-1574.e1 (2011).
101. Erbs S, Linke A, Adams V et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ. Res. 97(8), 756-762 (2005).
102. Boyle AJ, Whitbourn R, Schlicht S et al. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int. J. Cardiol. 109(1), 21-27 (2006).
103. Tuma J, Fernandez-Vina R, Carrasco A et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J. Transl. Med. 9, 183 (2011).
104. Losordo DW, Henry TD, Davidson C et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ. Res. 109(4), 428-436 (2011).
105. Losordo DW, Kibbe MR, Mendelsohn F et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ. Cardiovasc. Interv. 5(6), 821-830 (2012).
106. Nowbar A, Mielewczik M, Karavassilis M et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 28:348 (2014).
107. Povsic TJ, Junge C, Nada A et al. A Phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am. Heart J. 165(6), 854-861 (2013).
108. Muylaert DE, Fledderus JO, Bouten CV, Dankers PY, Verhaar MC. Combining tissue repair and tissue engineering; bioactivating implantable cell-free vascular scaffolds. Heart 100(23), 1825-1830 (2014).
109. McAllister TN, Maruszewski M, Garrido SA et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet 373(9673), 1440-1446 (2009).
110. Wojakowski W, Pyrlik A, Krol M et al. Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial). Minerva Cardioangiol. 61(3), 301-311 (2013).
111. Silber S, Damman P, Klomp M et al. Clinical results after coronary stenting with the Genous Bio-engineered R stent: 12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. Eurointervention 6(7), 819-825 (2011).
112. Klomp M, Beijk MA, Varma C et al. 1-year outcome of TRIAS HR (TRI-Stent Adjudication Study-High Risk of Restenosis). JACC Cardiovasc. Interv. 4(8), 896-904 (2011).
113. Takabatake S, Hayashi K, Nakanishi C et al. Vascular endothelial growth factor-bound stents: application of in situ capture technology of circulating endothelial progenitor cells in porcine coronary model. J. Interv. Cardiol. 27(1), 63-72 (2014).
114. Pernagallo S, Tura O, Samuel K et al. Novel biopolymers to enhance endothelialisation of intra-vascular devices. Adv. Healthc. Mater. 1(5) 646-656 (2012).
115. Lim W-H, Seo W-W, Choe W et al. Stent coated with antibody against vascular endothelial-cadherin captures endothelial progenitor cells, accelerates re-endothelialization, and reduces neointimal formation. Arterioscler. Thromb. Vasc. Biol. 31(12), 2798-2805 (2011).
116. Haude M, Lee SWL, Worthley SG et al. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc. Interv. 6(4), 334-343 (2013).